Berlin, 19.07.2019 – BIOCOM is part of the new EU project COMBINE, which will develop new solutions for the development of antimicrobial agents.
The increasing ineffectiveness of antibiotic agents due to the increasing antibiotic resistance (AMR) of pathogens poses a serious threat to the health of people all over the world. The AMR Accelerator Programme of the Innovative Medicines Initiative (IMI) will initiate a number of development projects to accelerate the discovery of new compounds to treat and prevent infections with resistant germs. COMBINE is a sub-project of the IMI AMR Accelerator.
As part of the project, BIOCOM will be responsible for work package 3 “Communication, Dissemination & Networking”. BIOCOM will develop and implement communication and dissemination strategies to strengthen interactions between AMR Accelerator participants and stakeholders in the EU and worldwide. Other partners include the University of Uppsala, the BEAM Alliance, GlaxoSmithKline, Evotec, the Paul Ehrlich Institute and many others.